Kevin Sidow has been President and Chief Executive Officer for Moximed, Inc since 2004. Prior to this he was President and CEO for St. Francis Medical Technologies, Inc., a privately held company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. The Company raised a total of $28 million in venture capital. In January 2007, St. Francis Medical Technologies, Inc. was sold for $725 million to Kyphon, Inc. Prior to joining SFMT, Kevin was the Worldwide President of DePuy Inc. As former Worldwide President of DePuy, he oversaw the global orthopaedic, spine, trauma, and sports medicine businesses and has over 20 years of orthopaedic medical device experience. His responsibilities included the combined worldwide reconstructive business (hips, knee, extremities, operating room products, ACE and casting), Spine, Mitek (sports medicine) and Biologics with annual revenue responsibility of over $3 billion.
Justin Saliman, M.D.
Founder and Chief Medical Officer, Director
Dr. Justin Saliman practices orthopaedic surgery with a sports focus at Cedars-Sinai Hospital in Los Angeles. He founded and ran the incubator Revolutionary Surgical Device, LLC in late 2007 which went on to create SuturePro Technologies, LLC and Advanced Meniscus Technologies, LLC in 2009. These companies were merged in 2010 to form Ceterix Orthopaedics. Justin completed medical school at the University of Colorado School of Medicine in his hometown of Denver. He completed his residency in orthopaedic surgery at St. Lukes – Roosevelt Hospital center of Columbia University in New York City and a sports fellowship at Stanford University in Palo Alto.
President and CEO, Director
John has 27 years of sales, marketing, and general management experience in medical devices. John started his career at American Hospital Supply (acquired by Baxter International) and has spent the past 20 years at start-ups, including DVI (acquired by Eli Lily), Perclose (acquired by Abbott Laboratories), Emphasys Medical (acquired by Pulmonx) and Ventus Medical. He has served on numerous Boards including Emphasys Medical, Ventus Medical, Disc Dynamics, Zeltiq (ZLTQ), Advanced Stent Technologies (acquired by Boston Scientific) and LuMend (acquired by Johnson & Johnson). John holds B.A. degrees in Economics and Psychology from the University of California, Los Angeles and an M.B.A. from the UCLA Anderson Graduate School of Management.
David Allison, Ph.D. has been a venture capital investor since 2006 and is currently a Principal at 5AM Ventures in San Francisco. He was previously at firms including Versant Ventures, Split Rock Partners and PTV Sciences. During his career, David has been involved with companies such as Aprea, Crinetics, Holaira, Ardian (acquired by Medtronic), Histogenics (Nasdaq: HSGX), RF Surgical (acquired by Medtronic), and Twelve (acquired by Medtronic). David also spent time with SurModics in its diagnostics and drug discovery business unit and as a NSF Research Fellow at The Cleveland Clinic Foundation’s Heart Valve Laboratory. David received a Ph.D. in Bioengineering from Rice University and a B.S.E. in Biomedical Engineering from The University of Iowa.
Kirk Nielsen joined Versant in 2006 from Medtronic, where he worked in sales & marketing in the company’s Cardiac Rhythm Management division. Previously, he spent time at Fluidigm (a Versant portfolio company) and he also served as a consultant at Bain & Company, where he advised clients in healthcare, private equity, and other industries. Prior to his business career, Kirk was a professional hockey player. At Versant, Kirk has led or co-led investments in Biotie (public/acquired), Cameron Health (acquired), CardiAQ (acquired), Lutonix (acquired), NeuWave Medical (acquired), Sequent Medical (acquired), Ceterix Orthopaedics, Holaira, Inari Medical, Metavention, Respicardia, Veran Medical, and Zyga Technology. Based in Minneapolis, he also leads the firm’s activities in the Midwest. Kirk earned a biology degree with honors from Harvard College, where he won the John P. Reardon, Jr. award as the school’s most outstanding scholar-athlete, and an MBA from Harvard Business School, where he was a Baker Scholar.
Charles Warden has been an active medical device venture investor since 1992 and is currently Managing Director, Versant Ventures. Prior to joining Versant he was a general partner at Schroder Ventures Life Sciences (now SV Life Sciences) where he led SV’s medical device activity. Charles has served on numerous medical device company boards, including the following currently: AcuFocus, Celula, Concentric Medical, ForSight Vision4, Glumetrics, Halscion, Ocular Therapeutix and WaveTec. Since its inception, Charles has been actively involved with several medical device incubators including The Innovation Factory, ForSight Labs, and The Foundry.